CFMS Conformis

Conformis, Inc. to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

Conformis, Inc. to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

BILLERICA, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s executive management team will participate in the 2020 Wells Fargo Virtual Healthcare Conference taking place September 9-10, 2020, in one-on-one meetings.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.  Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.  In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit . To receive future releases in e-mail alerts, sign up at .

Contact

Investor Contact:
Investor Relations
 
(781) 374-5598
EN
02/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conformis

 PRESS RELEASE

restor3d Completes Acquisition of Conformis

restor3d Completes Acquisition of Conformis Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased tr...

 PRESS RELEASE

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conform...

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, und...

 PRESS RELEASE

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders ...

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will a...

 PRESS RELEASE

Conformis Reports Second Quarter 2023 Financial Results

Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue ...

 PRESS RELEASE

Conformis Announces Definitive Agreement to be Acquired by restor3d fo...

Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash Combination creates a leading personalized 3D-printed orthopedic medical device company DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approxi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch